Genovis Q4 2024: Initial take - Redeye

Redeye's provides its initial take on Genovis' year-end report which came in softer than we had estimated, albeit still showing strong growth in the enzyme business and expanding profitability. We anticipate making minor revisions to our financial projections and fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1073733/genovis-q4-2024-initial-take?utm_source=finwire&utm_medium=RSS